Loading...
Docoh

Bristol-Myers Squibb (BMY)

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Company profile

Ticker
BMY, CELG-RI
Exchange
Website
CEO
Giovanni Caforio
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
1096271 BC ULC • 345 Park LLC • 9643435 Canada Inc. • Abraxis BioScience Australia Pty Ltd. • Abraxis BioScience International Holding Company, Inc. • Abraxis BioScience Puerto Rico, LLC • Abraxis BioScience, Inc. • Abraxis BioScience, LLC • AbVitro LLC • Acetylon Pharmaceuticals, Inc. ...
IRS number
220790350

BMY stock data

Calendar

27 Jul 22
19 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 10.96B 10.96B 10.96B 10.96B 10.96B 10.96B
Cash burn (monthly) 539.67M 36.42M (no burn) (no burn) (no burn) (no burn)
Cash used (since last report) 907.17M 61.22M n/a n/a n/a n/a
Cash remaining 10.05B 10.9B n/a n/a n/a n/a
Runway (months of cash) 18.6 299.3 n/a n/a n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Jul 22 Hirawat Samit Common Stock, $0.10 par value Payment of exercise Dispose F No No 76.84 4,786 367.76K 21,292
1 Jul 22 Hirawat Samit Common Stock, $0.10 par value Option exercise Acquire M No No 0 9,356 0 26,078
1 Jul 22 Hirawat Samit RSU Common Stock, $0.10 par value Option exercise Dispose M No No 0 9,356 0 9,357
1 Jul 22 Michelle Weese Common Stock, $0.10 par value Payment of exercise Dispose F No No 76.84 682 52.4K 1,203
1 Jul 22 Michelle Weese Common Stock, $0.10 par value Option exercise Acquire M No No 0 1,885 0 1,885
1 Jul 22 Michelle Weese RSU Common Stock, $0.10 par value Option exercise Dispose M No No 0 1,885 0 5,655
30 Jun 22 Haller Julia A Deferred Share Units Common Stock, $0.10 par value Grant Acquire A No No 77 438.312 33.75K 15,654.671
30 Jun 22 Samuels Theodore R. II Deferred Share Units Common Stock, $0.10 par value Grant Acquire A No No 77 633.117 48.75K 32,786.051
30 Jun 22 Derica W Rice Deferred Share Units Common Stock, $0.10 par value Grant Acquire A No No 77 470.779 36.25K 11,407.8
74.7% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 2427 2450 -0.9%
Opened positions 144 203 -29.1%
Closed positions 167 139 +20.1%
Increased positions 919 954 -3.7%
Reduced positions 1011 965 +4.8%
13F shares Current Prev Q Change
Total value 122.79B 117.09B +4.9%
Total shares 1.59B 1.6B -0.6%
Total puts 20.77M 22.23M -6.6%
Total calls 23.68M 27.43M -13.7%
Total put/call ratio 0.9 0.8 +8.2%
Largest owners Shares Value Change
Vanguard 196.83M $15.16B -0.8%
BLK Blackrock 170.65M $13.14B +2.0%
JPM JPMorgan Chase & Co. 97.76M $7.53B +4.1%
STT State Street 92.93M $7.2B -1.6%
FMR 71.88M $5.53B +7.2%
BAC Bank Of America 46.64M $3.59B +65.2%
Capital International Investors 38.1M $2.93B +66.4%
Geode Capital Management 38.02M $2.92B +1.2%
MS Morgan Stanley 36.17M $2.79B +31.2%
Wellington Management 35.76M $2.75B -15.9%
Largest transactions Shares Bought/sold Change
BAC Bank Of America 46.64M +18.4M +65.2%
LGEN Legal & General 0 -16.38M EXIT
Capital International Investors 38.1M +15.2M +66.4%
Parametric Portfolio Associates 0 -10.44M EXIT
Dodge & Cox 18.35M -8.65M -32.0%
MS Morgan Stanley 36.17M +8.61M +31.2%
Wellington Management 35.76M -6.76M -15.9%
Natixis 5.68M +4.89M +616.2%
FMR 71.88M +4.86M +7.2%
M&G Investment Management 0 -4.53M EXIT

Financial report summary

?
Risks
  • Increased pricing pressure and other restrictions in the U.S. and abroad continue to negatively affect our revenues and profit margins.
  • We may experience difficulties or delays in the development and commercialization of new products. Our ability to replace revenue from products that lose patent protection is directly dependent on our ability to successfully commercialize new products in a timely manner.
  • The public announcement of data from our clinical studies, or those of our competitors, or news of any developments related to our, or our competitors’, products or late-stage compounds may cause significant volatility in our stock price and depending on the data, may result in an adverse impact on our business, financial condition or results of operations. If the development of any of our key late-stage product candidates is delayed or discontinued or a clinical study does not
  • meet one or more of its primary endpoints, our stock price could decline significantly and there may be an adverse impact on our business, financial condition or results of operations.
  • We could lose market exclusivity of a product earlier than expected.
  • We face intense competition from other manufacturers and expect to see increasing market penetration of lower-priced generic products.
  • We could experience difficulties, delays and disruptions in the manufacturing, distribution and sale of our products.
  • We may encounter difficulties integrating ours and Celgene’s businesses and operations and, therefore, may not fully realize the projected benefits from our acquisition of Celgene.
  • Litigation claiming infringement of intellectual property may adversely affect our future revenues and operating earnings.
  • Adverse outcomes in legal matters could negatively affect our business.
  • We are subject to a variety of U.S. and international laws and regulations.
  • Changes to tax regulations could negatively impact our earnings.
  • The failure of third parties to meet their contractual, regulatory and other obligations could adversely affect our business.
  • Product labeling changes for our marketed products could result in a negative impact on revenues and profit margins.
  • The illegal distribution and sale by third parties of counterfeit or unregistered versions of our products or stolen products could have a negative impact on our revenues, earnings, reputation and business.
  • Increased use of social media platforms present risks and challenges.
  • We are dependent on information technology and our systems and infrastructure face certain risks, including from cybersecurity breaches and data leakage.
  • Failure to execute our business strategy could adversely impact our growth and profitability.
  • We depend on several key products for most of our revenues, cash flows and earnings.
  • Third-party royalties represent a significant percentage of our pretax income and operating cash flow.
  • Failure to effectively manage acquisitions, divestitures, alliances, joint ventures and other portfolio actions could adversely impact our future results. In addition, any businesses or assets that we acquire in the future may underperform, we may not be able to successfully integrate them into our existing business and the occurrence of a number of unexpected factors could prevent or substantially delay the consummation of an anticipated acquisition, divestiture or merger.
  • Failure to attract and retain highly qualified workforce could affect our ability to successfully develop and commercialize products.
  • Our significant additional indebtedness that we incurred in connection with the Celgene and MyoKardia acquisitions could have negative consequences.
  • Adverse changes in U.S. and global economic and political conditions could adversely affect our profitability.
  • There can be no guarantee that we will pay dividends or repurchase stock.
  • Our amended bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain lawsuits between us and our stockholders, which could limit our stockholders’ ability to obtain a judicial forum that it finds favorable for such lawsuits and make it more costly for our stockholders to bring such lawsuits, which may have the effect of discouraging such lawsuits.
  • The COVID-19 pandemic is affecting our business and could have a material adverse effect on us.
Management Discussion
  • (a)    Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
  • (b)    Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales.
  • •U.S. revenues for the second quarter of 2022 and year-to-date increased due to Eliquis, our New Product Portfolio and Opdivo. Average U.S. net selling prices increased 4% year-to-date compared to the same period a year ago.

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: addressed, agreed, barred, begun, Bhd, BridgeBio, chemoimmunotherapy, cisplatin, clawback, cognitive, dataset, deadline, discharge, disposition, doubled, driven, exhausted, factual, haematopoietic, hospital, inactive, ineligible, infection, lapse, LOTTE, lt, Malaysia, mortality, mRNA, multicenter, Nanocopoeia, NTRK, Oncogen, oncogenic, PAISLEY, permission, PILOT, plaque, platinum, POETYK, Point, post, precision, preserved, prohibit, PSO, Qilu, recommendation, recommended, recoverable, repotrectinib, responded, Responder, responding, satisfaction, Sdn, seroconversion, SLE, sponsored, statute, SUNBEAM, Syracuse, thalamic, tranche, Turning, VAT, waiting, withholding
Removed: accepted, adjudication, administratively, approach, cabometyx, Columbia, enrollment, Ireland, lack, Minnesota, PDUFA, Pennsylvania, randomized, relation, Republic, rest, Russia, significance, statistical, Sweden, True